IPW
AVDL

Impact Partnership Wealth’s Avadel Pharmaceuticals AVDL Stock Holding History

Impact Partnership Wealth’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-156
Closed -$2.57K – 1014
2023
Q2 		$2.57K Buy
+156
New +$2.03K ﹤0.01% 605

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Impact Partnership Wealth's AVDL Position: Q3 2023 in Review

Impact Partnership Wealth sold out of Avadel Pharmaceuticals (AVDL) in Q3 2023, closing a stake of 156 shares — an estimated $2.57K sold.

Impact Partnership Wealth first reported a position in AVDL in Q2 2023 and held it in 1 quarter. The position peaked at $2.57K in Q2 2023. 99 funds tracked by Wall St. Rank hold AVDL as of Q3 2023.

  • Impact Partnership Wealth reported no remaining Avadel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 156 Avadel Pharmaceuticals shares in Q3 2023, an estimated $2.57K.
  • Impact Partnership Wealth first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's Avadel Pharmaceuticals position peaked at $2.57K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.